Focus: Partner Therapeutics is a Massachusetts-based biotech company focused on biologics development across oncology, neurology, infectious diseases, and respiratory indications. The company operates with a lean structure and maintains an active pipeline spanning multiple therapeutic areas.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
4 recent layoff filings (12 mo) — 129 affected
Source: state DOL filings via Big Local News
No open roles listed right now. Follow Partner Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Partner Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
ANDA product already beyond loss of exclusivity with minimal commercial relevance.
Help build intelligence for Partner Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Brand formulation (tablets and suspension) with nearing patent cliff; represents core marketed product in infectious disease space.
Duplicate product entry in source data; same indication and lifecycle as primary ALINIA listing.
ANDA product well beyond loss of exclusivity with limited commercial value.
Duplicate ANDA entry; same product and lifecycle status as primary SUCRALFATE listing.
Third duplicate of ALINIA in product portfolio data; indicates data quality issues in source listing.
Second ANDA entry for nitazoxanide; duplicate of first product listing.
2 discontinued, 3 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Multiple, overlapping layoffs across geographies within 8 months suggest serious financial or strategic distress; substantial restructuring risk remains.